Vimarsana
Biggest News Aggregation in the World

Page 8 - Topical Solution News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Topical Solution. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Topical Solution Today - Breaking & Trending Today

Lupin gets tentative approval for Efinaconazole Topical Solution - Vimarsana News

Lupin gets tentative approval for Efinaconazole Topical Solution

Lupin announced that it has received tentative approval for its Efinaconazole Topical Solution, 10%, from the United States Food and Drug Administration, to market a generic equivalent of Jublia Topical Solution, 10%, of Bausch Health Americas, Inc. Efinaconazole Topical Solution, 10%, is indicated for the topical treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes. Efinaconazole Topical Solution, 10%, (RLD: Jublia) had estimated annual sales of $222.9 million in the U.S. (IQVIA MAT September 2020). The announcement was made after market hou...

RIL, Lupin, DLF in focus - Vimarsana News

RIL, Lupin, DLF in focus

Shares of Reliance Industries (RIL) will be in focus. RIL has entered into definitive agreements to acquire the shares held by IMG Singapore Pte. Ltd in IMG-R, for a cash consideration not exceeding Rs 52.08 crore. Post completion of acquisition, IMG-R will become a wholly-owned subsidiary of the company and will be rebranded by the company. IMG Reliance (IMG-R) is a joint venture between IMG Worldwide LLC (IMG) and RIL. IMG Singapore Pte. Ltd., a wholly owned subsidiary of IMG, holds 50% of the share capital of IMG-R. IMG-R is engaged in the business of creation, management, implementation a...

Lupin receives USFDA tentative approval for Efinaconazole Topical Solution - Vimarsana News

Lupin receives USFDA tentative approval for Efinaconazole Topical Solution

Lupin has received tentative approval for its Efinaconazole Topical Solution, 10%, from the United States Food and Drug Administration, to market a generic equivalent of Jublia Topical Solution, 10%, of Bausch Health Americas, Inc. Efinaconazole Topical Solution, 10%, is indicated for the topical treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes. Efinaconazole Topical Solution, 10%, (RLD: Jublia) had estimated annual sales of USD 222.9 million in the U. S. (IQVIA MAT September 2020). Powered by Capital Market - Live News (This story has ...

Lupin receives tentative approval for Efinaconazole Topical Solution - Vimarsana News

Lupin receives tentative approval for Efinaconazole Topical Solution

Lupin receives tentative approval for Efinaconazole Topical Solution

Soap vs. Sanitizer: Only One Kills - Vimarsana News

Soap vs. Sanitizer: Only One Kills

Soap vs. Sanitizer: Only One Kills By Frank Long, MS, Editorial Director Hand sanitizers are sold in sizes small enough to be carried in a pocket and used instantly without running water. Compared to clunky bar soaps today’s hand sanitizers win the convenience argument hands down. However, something alarming was recently found in certain hand sanitizers: poisonous, colorless, flammable methanol. Danger is Skin Deep According to the Centers for Disease Control and Prevention (CDC) in a health advisory issued July 5, methanol is a type of toxic alcohol that can be lethal if absorbed through ...